More Like this

1. A Protein-Protein Interactome for an African Cichlid

   https://doi.org/10.1145/3388440.3414916  

   Preising, Gabriel A.; Faber-Hammond, Joshua J.; Renn, Suzy C.; Ritz, Anna (January 2020, Proceedings of the 11th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics)

   null (Ed.)
2. Protein-protein interactions in neurodegenerative diseases: A conspiracy theory

   https://doi.org/10.1371/journal.pcbi.1008267  

   Thompson, Travis B.; Chaggar, Pavanjit; Kuhl, Ellen; Goriely, Alain (October 2020, PLOS Computational Biology)

   Csikász-Nagy, Attila (Ed.)
3. Polypeptide-protein conjugation: A new paradigm for therapeutic protein delivery

   https://doi.org/10.1016/j.jconrel.2025.113953  

   Zhang, Xiao; Fu, Shiwei; Zhao, Bowen; Liu, Yilin; Seruya, Ronald S; Zhang, Fuwu (August 2025, Journal of Controlled Release)

   Proteolysis-targeting chimera (PROTAC) has emerged as a groundbreaking therapeutic strategy by hijacking the endogenous ubiquitin proteasome system (UPS) for targeted protein degradation. These heterobifunctional molecules recruit E3 ligases to recognize the protein of interest (POI) and facilitate its ubiquitination, leading to subsequent proteasomal degradation. Compared to conventional protein inhibitors, PROTACs offer a broader range of target degradation and remain effective even against proteins with drug-resistant mutations. Moreover, PROTACs function in a catalytic manner to degrade POIs, allowing for significantly lower administration dosages. In recent years, PROTACs have shown great promise in cancer therapy due to their high efficiency and broad applicability. However, their clinical applications remain challenging due to low bioavailability, limited tumor-targeting ability, and potential side effects. Utilizing nanomedicine for the delivery of PROTACs offers a promising strategy to enhance bioavailability, improve tumor selectivity, and minimize toxicity, thereby advancing their applications in cancer treatment. In this review, we outline the fundamental design principles of PROTACs, summarize the latest progress of nanomedicines from molecular design to drug delivery for improved tumor treatment, introduce PROTAC-based combination therapies and emerging design strategies, and discuss current challenges and future prospects of PROTAC nanomedicines toward clinical translation. 

   more » « less
4. The BR-body proteome contains a complex network of protein-protein and protein-RNA interactions

   https://doi.org/10.1016/j.celrep.2023.113229  

   Nandana, Vidhyadhar; Rathnayaka-Mudiyanselage, Imalka W; Muthunayake, Nisansala S; Hatami, Ali; Mousseau, C Bruce; Ortiz-Rodríguez, Luis A; Vaishnav, Jamuna; Collins, Michael; Gega, Alisa; Mallikaarachchi, Kaveendya S; et al (October 2023, Cell Reports)
5. DPPIN: A Biological Repository of Dynamic Protein-Protein Interaction Network Data

   https://doi.org/10.1109/BigData55660.2022.10020904  

   Fu, Dongqi; He, Jingrui (December 2022, IEEE International Conference on Big Data)